UK Markets closed

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
45.45-1.51 (-3.22%)
As of 03:36PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.34
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 384.83
52-week low 326.81
50-day moving average 338.12
200-day moving average 349.91

Share statistics

Avg vol (3-month) 3861.42k
Avg vol (10-day) 3813.11k
Shares outstanding 5104.53M
Implied shares outstanding 6N/A
Float 8102.82M
% held by insiders 12.65%
% held by institutions 167.02%
Shares short (14 Jul 2022) 44.93M
Short ratio (14 Jul 2022) 45.11
Short % of float (14 Jul 2022) 45.44%
Short % of shares outstanding (14 Jul 2022) 44.66%
Shares short (prior month 14 Jun 2022) 44.98M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 316 Nov 2011

Financial highlights

Fiscal year

Fiscal year ends 29 Sept 2021
Most-recent quarter (mrq)30 Mar 2022

Profitability

Profit margin -42.44%
Operating margin (ttm)-44.99%

Management effectiveness

Return on assets (ttm)-10.15%
Return on equity (ttm)-24.91%

Income statement

Revenue (ttm)263.42M
Revenue per share (ttm)2.52
Quarterly revenue growth (yoy)362.70%
Gross profit (ttm)138.29M
EBITDA -108.85M
Net income avi to common (ttm)-111.8M
Diluted EPS (ttm)-1.36
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)401.9M
Total cash per share (mrq)3.8
Total debt (mrq)25.61M
Total debt/equity (mrq)5.66
Current ratio (mrq)3.01
Book value per share (mrq)3.92

Cash flow statement

Operating cash flow (ttm)-52.34M
Levered free cash flow (ttm)-11.85M